Clinical trial · Interventional
Fluorescent-labeled IgG for Liver Tumor Detection
Intraoperative Liver Tumor Imaging Using Fluorescent-labeled Human IgG
NCT05394246CI-TRIAL-00069208unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to evaluate whether intraoperative fluorescence imaging using fluorescent-labeled IgG probe (FluoAB) can help distinguish the tumor and the liver cirrhosis (or the liver parenchyma). The main purposes of this study include: * To validate the safety and effectiveness of using FluoAB in hepatic surgery. * To raise the surgical precision with guidance by FluoAB fluorescence imaging.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FluoAB | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- FluoAB intraoperative fluorescence imaging
- description
- The patients will receive an injection of FluoAB. Surgery will be performed with guidance by FluoAB fluorescence imaging.
- interventionNames
- Drug: FluoAB
Primary outcomes (2)
- measure
- Tumor imaging precision
- timeFrame
- Update with an average of 2 weeks.
- description
- Sensitivity and specificity of hepatic malignancy detection by fluoAB intraoperative imaging.
- measure
- Tumor lesions
- timeFrame
- Immediately after the hepatic surgery.
- description
- Numbers of intraoperatively detected tumor lesions.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who have been diagnosed with liver tumor. 2. Planned to receive hepatectomy. 3. Liver function Child-Pugh A/B. 4. The expected lifetime is longer than 6 months. 5. Approved to sign the informed consent. Exclusion Criteria: 1. Enrolled in other trials in the past 3 months. 2. Metastatic lesions were found. 3. Undesirable function of heart, lung, kidney, or any other organs. 4. Unable to tolerate a hepatectomy. 5. The researchers considered inappropriate to be included.
References
Publications (0)
Data not yet available
No reference posted for this study.